# Hyperandrogenism in women: Diagnosis and management

Adam Balen Department of Reproductive Medicine Leeds Teaching Hospitals, UK

ESHRE Campus "Old and New Hormones" Budapest 2009

### **Learning Objectives**

- 1. Hyperandrogenism and new definitions of the polycystic ovary syndrome
- 2. Pathophysiology, genetics and ethnic variations
- **3.** Approaches to management of HA

# **Causes of androgen excess**

### • PCOS


- Late onset congenital adrenal hyperplasia
- Androgen secreting tumours
- Cushing's syndrome

### Hyperandrogenism:

Hirsutism:

Alopecia:

Subjective (patient and physician) Quantify Ferriman Gallwey Score Ethnic variations



Androgen mediated / iron deficiency

Acne...





2

R

Q Solo 54% of women over 25y have physiological acne 3% clinical acne Correlates variably with hyperandrogenemia

Hirsutism – distribution varies, F&G score – still subjective and observer variability - not standardised

All symptoms and effect on QoL amplified by obesity and each other

### **Biochemistry of Hyperandrogenism**

- Testosterone : free or total ? (< 5nmol/l)</p>
- SHBG surrogate for insulin resistance
- Free Androgen Index (T/SHBG)x100
- Androstenedione, DHEAS, 17-OH P .... ?

Kane et al, Ann Clin Biochem 2007; 44: 5-15 Barth & Balen, Clin Endocrinol 2007; 67: 811

# Controversies

- How to assess HA biochemically? Mass spectrometry superior to immunoassays
- Variations:

Diurnal (am > pm), Cyclical (luteal > follicular) Seasonal (summer > winter)

- Age-related changes
- Ethnic differences

The Rotterdam ESHRE/ASRM Consensus Group Revised 2003 Diagnostic Criteria for PCOS

### 2 out of 3 criteria required

- Oligo- and/or anovulation i.e. oligomenorrhoea or amenorrhoea
- Weight Hyperandrogenism
   clinical and/or biochemical
- Polycystic ovaries
  Exclusion of other aetiologies

Human Reproduction 2004; 19: 41-47. Fertility & Sterility, 2004; 81: 19-25.

Ultrasound Assessment of the Polycystic Ovary: International Consensus Definitions

The polycystic ovary contains 12 or more follicles measuring 2-9 mm in diameter

and/or

increased ovarian volume (>10 cm<sup>3</sup>)

Balen, Laven, Tan & Dewailly; Hum Reprod Update 2003 ESHRE/ASRM Consensus 2003

# Polycystic Ovary Syndrome: Investigations

1. Androgen profile:

Testosterone (SHBG, 170H-P, adrenal profile)

- 2. FSH, LH, <u>+</u> oestradiol, AMH?
- 3. Prolactin / TFTs
- 4. Ultrasound scan
- 5. Assessment glucose tolerance / insulin resistance: GTT, lipid profile

### **Testosterone / DHEAS**

- **The contrast of a second seco**
- Tight feedback of T in men, via ACTH, but not DHEA
- Neither T nor DHEA regulated by feedback in women

Oligomenorrhoea:> 90% PCOSAmenorrhoea:~ 30 - 50% PCOSAnovulatory infertility:> 90% PCOSAcne in women:> 95% PCOSHirsutism:> 95% PCOS

Female caucasian population:20 – 33% PCO15 – 25% PCOS

U.K. South Asian population: 50% PCOS

- 1. Hyperandrogenism and new definitions of the polycystic ovary syndrome
- 2. Pathophysiology, genetics and ethnic variations
- **3.** Approaches to management of HA



#### **Hyperandrogenism** Menstrual disturbances

testosterone
 luteinising hormone



#### **Hyperandrogenism** Menstrual disturbances

testosterone
 luteinising hormone

### **Elevated Luteinising Hormone:**

- not mandatory for diagnosis, elevated in 40%
- most likely to be elevated in slim women
- may help predict outcome of fertility therapy:
  - Worse outcome after CC if elevated day 8
  - Better prognosis for response to ovarian drilling



#### Hyperandrogenism Menstrual disturbances

testosterone
luteinising hormone
insulin



#### Hyperandrogenism Menstrual disturbances

↑ testosterone, ↓ SHBG
↑ luteinising hormone
↑ insulin

### **Insulin Resistance and PCOS**

- Failure of insulin action at receptor
- Selective insulin resistance:

Glucose uptake by cells impaired

**Trophic actions of insulin continue** 

Insulin augments  $LH \rightarrow \uparrow$  testosterone

### "Compensated" insulin resistance with normal glucose tolerance

# Impaired glucose tolerance (IGT)

**Type 2 Diabetes** 

Volunteer Study of Women's Health

224 female volunteers, 17-25y

- 33% polycystic ovaries
- 80% with polycystic ovaries had a least one feature of PCOS

Michelmore et al, Clin Endocrinol 1999; 51: 779


### 224 women 17-25y, 33% polycystic ovaries

	<b>PCO</b>	<u>Normal ovaries</u>	<u>P</u>
BMI kg/m <sup>2</sup>	23.3	23.1	n.s.
% body fat	30.4	29.4	0.048
Birthweight kg	3.49	3.28	0.004
Testo. nmol/l	2.67	2.47	0.03

Differences between women with polycystic ovaries only and with polycystic ovary *syndrome*?

The presence of pco represents a milder end of the PCOS spectrum

Balen, Homburg, Franks, BMJ 2009



after Dewailly







### **The Genetics of PCOS**

Probably a complex genetic trait disorder

- Different combinations of genetic variants influence differential expression of the syndrome
- Multi-factorial e.g. environmental influences:
  - in-utero programming of hypothalamus
    - insulin homeostasis
  - lifestyle: diet / exercise

PCOS in South Asians and Caucasians living in the U.K.

**Case control study of anovulatory PCOS:** 

**47 South Asian PCOS and 11 controls** 

**40** Caucasian PCOS and **22** controls

Wijeyaratne et al, Clin Endocrinol 2002; 57: 243

S. Asians had significantly:

↓ age onset hirsutism
 ↑ hirsutism, acne & acanthosis nigricans
 p < 0.01</li>
 similar BMI & W:H

similar total Testosterone  $\uparrow$  insulin and  $\downarrow$  SHBG

**p < 0.001** 

Wijeyaratne et al, Clin Endocrinol 2002; 57: 243 Wijeyeratne et al, Clin Endocrinol 2004; 60: 560 Palep-Singh et al. J Reprod Med 2008; 53:117


- 1. Hyperandrogenism and new definitions of the polycystic ovary syndrome
- 2. Pathophysiology, genetics and ethnic variations
- 3. Approaches to management of HA

### **Hyperandrogenism:**

### Alopecia:



### Hirsutism: subjective Ferriman Gallwey Score





### Hyperandrogenism

- Acne
- Hirsutism
- Alopecia


Negative impact on self esteem, social interaction, Ability to achieve at work

Combined with menstrual/fertility problems - negative feelings about feminity The PCOS Health-Related Quality of Life Questionnaire (PCOSQ)

Women and adolescents with PCOS

Worst health concerns: weight infertility emotional limitations and poor energy hirsutism

> Jones *et al,* Human Reprod 2004; 2007; Hall *et al,* ESHRE 2007 Jones *et al,* Hum Reprod Update 2008; 14:15



### Acne in PCOS

- Seborrhoea
  - an indicator of poor response to antibiotics
- Persistent
- Refractory to therapy
- Later onset
- Associated with
  - Irregular menses
  - Hirsutism
  - Obesity
  - Androgenic alopecia



# Acanthosis Nigricans HAIRAN

- Mucocutaneous eruption
  - Axillae, flexures, nape of the neck
  - Increased pigmentation and papillomatosis
- Cutaneous marker associated with insulin resistance and compensatory increased secretion
- May present more commonly in adolescents with PCOS – incidence 1-3%



# **Actions of Anti-Acne Therapies**


#### **Topical retinoids:**

- Normalise desquamation
- Reduce inflammatory response

#### Antibiotics:

- Reduce micro organisms
- Reduce inflammatory response

#### Benzoyl peroxide: ✓ Kills microorganisms



#### **Oral Isotretinoin:**

- Reduces sebum
- Normalise desquamation
- ✓ Inhibits P acnes growth
- Reduces inflammatory response

#### Hormones:

- Reduce sebum production
- Normalise desquamation

#### **Anti-Acne Therapies**



Hormones reduce sebum production

Antibiotics reduce inflammation and micro-organisms

Topical benzoyl peroxide kills micro-organisms

**Topical retinoids reduce inflammation** 



#### 1-2% adult female population have severe hirsutism

#### 80% of women in UK concerned about unwanted hair

#### **Definition:**

#### Excessive facial and / or body terminal hairs in a male pattern distribution

Results from excess androgen and the sensitivity of hair follicle to androgen



The impact of androgens on body hair

Vellus hair develops into terminal hair (secondary sexual hair)

Starts at puberty (adrenarche)

**Occurs over several hair cycles** 

Irreversible – treatments aim to destroy the stem cell population in hair follicles or to suppress androgen production

#### The impact of androgens on scalp hair

Androgenic alopecia: progressive loss of terminal scalp hair in genetically susceptible women Diffuse diminishing hair diameter, length and density



Pattern may embrace progressive thinning over the crown (Ludwig pattern) with preservation of hairline, or male-pattern with bitemporal recession

#### Weight loss

Physical removal:electrolysis, laser therapy shaving, depilatory creams

Eflornithine carboxylase

**Anti-androgen medication: COCP** 

EE2 / cyproterone acetate EE2 / drospirenone Spironolactone Flutamide, finasteride

Metformin

#### Weight loss

Physical removal:electrolysis, laser therapy shaving, depilatory creams

Eflornithine

**Anti-androgen medication: COCP** 

EE2 / cyproterone acetate EE2 / drospirenone Spironolactone Flutamide, finasteride

Metformin

Weight loss

Physical removal:electrolysis, laser therapy shaving, depilatory creams threading, plucking, epilators bleaching, camouflage, hairstyling wigs

# **Electrolysis / Electrical depilation**

Only permanent method, may take 24 months

Galvanic depilation: needle inserted into hair follicle and direct current applied which causes chemical reaction with salts in the tissue and destroys follicle

**Diathermic method:** uses alternating current to induce heat reaction which coagulates hair follicle (quicker but more regrowth)

www.electrolysis-bae-ltd.co.uk

#### Laser

Laser light (694-1064 nm) passes through skin absorbed by melanin in the follicle, converted to heat energy to destroy follicle

Target stem cell population where pigmented cells are populated

Most effective in anagen phase of hair growth

**Complete hair loss rarely achieved** 

#### Laser

Ideal patient fair skin and dark hair

Dark skin: risk of epidermal damage, pigmentary change, scarring and more pain

RCT in 88 women with PCOS reported reduced facial hair, anxiety and depression after 6m

Clayton et al Br J Dermatol 2005; 152:986-992

#### Weight loss

Physical removal:electrolysis, laser therapy shaving, depilatory creams

#### Eflornithine

**Anti-androgen medication: COCP** 

EE2 / cyproterone acetate EE2 / drospirenone Spironolactone Flutamide, finasteride

#### Metformin

# Eflornithine HCI 11.5% cream (Vaniqa)

Irreversible inhibitor of ornithine decarboxylase, the rate limiting step in production of polyamines

Expressed in proliferating bulb cells of anagen hair follicles

Applied twice daily

# Eflornithine

70% respond

**Reduces visibility and coarseness** 

# Eflornithine 11.5% cream

2 RCTs, published jointly 596 women (395 eflornithine vs 201 vehicle) 24 weeks

Significant improvement by 4-8 weeks

Overall success 33% vs 9% (clear or almost clear of visible terminal hair)

Less effective in non-white women 22% vs 37% Less effective in overweight

Wolfe et al Int J Dermatol 2007; 46:94

#### Weight loss

Physical removal:electrolysis, laser therapy shaving, depilatory creams

Eflornithine

**Anti-androgen medication: COCP** 

EE2 / cyproterone acetate EE2 / drospirenone Spironolactone Flutamide, finasteride

Metformin

#### **Principles of hormone treatment**

- Suppress adrenal & ovarian androgen production
- Increase binding of androgens to SHBG
- Impair peripheral conversion of precursors to active androgens
- Inhibit action of androgens at target tissue

#### Dianette EE2 35mcg + CPA 2mg

69.4% resolution in 140 women with PCOS for 60 cycles

**Response takes 6-9 months** 

**Check LFTS as rarely leads to liver damage** 

van der Spuy, Cochrane review 2003; 4:CD001125

### Dianette (D) vs D+20mg CPA vs D+100mg CPA

**CPA given days 1-10** 


Significant fall in clinical hair growth scores and hair diameter (face and body)

No significant differences between doses at 6 months

Trend towards a dose response

Barth et al Clin Endo 1991; 35:5

# Hyperandrogenism



#### Yasmin (EE2 30 mcg + drospirenone 3mg)

Well tolerated

Significant fall in clinical hair growth scores by 67% at 6m and 78% at 12m

Batuka et al F & S 2006 Palep-Singh et al Br J Fam Plan 2004

#### Weight loss

Physical removal:electrolysis, laser therapy shaving, depilatory creams

Eflornithine carboxylase

**Anti-androgen medication: COCP** 

EE2 / cyproterone acetate EE2 / drospirenone Spironolactone Flutamide, finasteride

Metformin

#### **Spironolactone vs Placebo**

2 trials assessing hirsutism

F-G fell: WMD 7.20, 95% CI -10.98 - -3.42

Subjective improvement: OR 7.18, 95% CI 1.96-26.28

Farquhar et al Cochrane Database 2002 McLellan et al Postgrad MJ 1989 Moghetti et al JCEM 2000

#### Weight loss

Physical removal:electrolysis, laser therapy shaving, depilatory creams

Eflornithine

**Anti-androgen medication: COCP** 

EE2 / cyproterone acetate EE2 / drospirenone Spironolactone Flutamide, finasteride

Metformin

# Flutamide

Licensed for prostate cancer only

Supresses hirsutism, but no better than other therapies

Fatal cases of cholestatic hepatitis

**Risk-benefit ratio unacceptable for benign conditions** 

Osculati & Castiglioni Lancet; 2006; 367: 1140

# **Finasteride**

Licensed for prostate cancer only

Supresses hirsutism, but no better than other therapies

#### Weight loss

Physical removal:electrolysis, laser therapy shaving, depilatory creams

#### Eflornithine

**Anti-androgen medication: COCP** 

EE2 / cyproterone acetate EE2 / drospirenone Spironolactone Flutamide, finasteride

#### **Metformin**

**Metformin vs Placebo** 

Insufficient evidence to demonstrate a benefit


**Metformin vs COCP** 

3 trials assessing hirsutism (F-G or subjective)

No difference (-0.18, 95% CI -0.67 - 0.32)

**COCP** better at suppressing androgen levels

*Costello et al Hum Reprod 2007; 22: 1200 Tang, Norman, Balen Cochrane Database 2009* 



#### Mean change in FG score in different drug groups

Meta-analysis, Conway et al 2007

# **Revised Cochrane Meta-analysis**

#### No clear role for metformin in treatment of hyperandrogenism

Tommy Tang, Rob Norman, Adam Balen 2009


#### Treatment of androgenic alopecia

#### Minoxidil


- increases duration of anagen, enlarges follicles
- 2% or 5% topical solution
- 1 ml to scalp twice daily, minimum 4 months
- up to 42.5% improvement over 32w

21 hydroxylase deficiency (95% of CAH) 1:5,000 – 1:20,000 births carrier status in 1:80 racial differences

classical salt wasting ~ 60% non-salt wasting ~ 20% late onset ~ 20%



(StAR = steroidogenic acute regulatory protein, delivers cholesterol to mitochondria)



Adrenal medulla may be suppressed by overgrown cortex, but of no pathological significance

Simple virilizing: defect expressed only in zona fasciculata

Salt-wasting: z. fasciculata and z. glomerulosa ass. with HLA BW47 & DR7 volume depletion, hypotension, reduced renal blood flow, raised PRA (suppression of PRA used to assess efficacy of treatment with fludrocortisone)

**Elevated 170H-progesterone** 

May require 250mcg ACTH test: cut-off 30 nmol/l

Require corticosteroid (hydrocortisone / prednisolone) Fludrocortisone, if salt losing

May require additional COCP

Ovulation induction difficult if progesterone elevated (suppress with additional prednisolone in follicular phase of cycle)

# **Relative strengths of glucocorticoids**

	Potency	Average daily dose (mg)
Hydrocortisone	1	20 - 30
Cortisone acetate	0.8	25 - 37.5
Prednisolone	5	5 - 10
Dexamethasone	40	0.5 - 0.75

Treatment usually with hydrocortisone

Monitor testosterone or androstenedione (latter not bound to SHBG ∴ useful if obese)

17OH-P fluctuates hourly and depends on previous dose of glucocorticoid

Prevention in pregnancy if previous history of affected child: Dexamethasone crosses placenta

# **Current Principals of Surgery in CAH**

Avoid vaginoplasty /clitoral reduction in infancy
 careful counselling and support of parents

Optimise endocrine control during childhood and puberty

Surgery best performed post-puberty
 full involvement of individual
 avoid clitoral reduction

# Summary

- **1.** PCOS main cause of hyperandrogenism
- 2. Definitions still debated and ethnic variations important
- **3.** Acne and hirsutism have major impact on QoL
- 4. Therapies combine physical and pharmaceutical approaches

# Acknowledgements

#### **University of Leeds**

Cath Hayden Tommy Tang Julie Glanville Manisha P-Singh Ephia Yasmin Helen Picton Julian Barth Paul Belchetz **University of Cambridge David Dunger** 

**University of Oxford Kathy Michelmore Martin Vessey** 

**University of Colombo Chandrika Wijeyaratne**